Evidence map›Paper›PMID 40791795›Full record

ReviewMaterials today. Bio2025

Organoid-on-a-chip (OrgOC): Advancing cystic fibrosis research.

Minjie Zheng, Elisa Erice, Huiyi Wang, Lei Zhang, Charles H Lawrie

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Minjie ZhengSchool of Microelectronics, Shanghai University, Shanghai, 201800, China.
Elisa EriceSino-Swiss Institute of Advanced Technology (SSIAT), Shanghai University, Shanghai, 201800, China.
Huiyi WangSino-Swiss Institute of Advanced Technology (SSIAT), Shanghai University, Shanghai, 201800, China.
Lei ZhangSchool of Microelectronics, Shanghai University, Shanghai, 201800, China.
Charles H LawrieSino-Swiss Institute of Advanced Technology (SSIAT), Shanghai University, Shanghai, 201800, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cystic fibrosis (CF) is an autosomal recessive disorder resulting from impaired anion transport in the epithelium of multiple organs, thereby affecting various physiological functions throughout the body. The heterogeneity of CF complicates drug development, highlighting the growing importance of individualized therapies. CF patient-derived organoid models and organ-on-a-chip (OOC) platforms are promising in vitro models for recapitulating CF pathology, owing to their high simulation fidelity, individualized therapeutic capabilities, cost-effectiveness, and high-throughput screening potential. This review systematically summarizes the technological development pathways of patient-derived organoids and OOC platforms for CF, along with recent advances in their applications to CF-related basic research, and particularly focuses on exploratory studies using organoid-on-a-chip (OrgOC) systems to elucidate CF pathogenesis and assess therapeutic approaches.

Indexed as

Cystic fibrosisOrganoidOrganoid-on-a-chipOrgan-on-a-chip

Identifiers

PMID40791795
PMCPMC12336816

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.